Grave’s Eye Ophthalmopathy Developing Following Radioiodine Therapy for Toxic Adenoma ()
ABSTRACT
The development of Grave’s ophthalmopathy following radioiodine treatment for Grave’s disease is well recognized. However, development of Grave’s ophthalmopathy following radioiodine therapy given for toxic adenoma or toxic nodular goiter has been reported but very rarely. Hereby, we reported a case of a 69-year-old male patient who developed ophthalmopathy after receiving 30 mCi (1110 mBq) 131 I radioiodine treatment for a toxic nodule. In addition, a review of the current literature with regards to this topic is presented.
Share and Cite:
H. Ahmadieh and I. Salti, "Grave’s Eye Ophthalmopathy Developing Following Radioiodine Therapy for Toxic Adenoma,"
Open Journal of Endocrine and Metabolic Diseases, Vol. 3 No. 6, 2013, pp. 259-262. doi:
10.4236/ojemd.2013.36035.